Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus Directory of Open Access Journals kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

A bactericidal tuberculosis drug regimen driven by inhibition of the terminal oxidases by pretomanid

Title: A bactericidal tuberculosis drug regimen driven by inhibition of the terminal oxidases by pretomanid
Authors: Nurlilah Ab Rahman; Samsher Singh; Thomas Wiggins; May Delos Santos; Garrett C Moraski; Marvin J Miller; Michael Berney; Kevin Pethe
Source: EMBO Molecular Medicine, Vol 18, Iss 3, Pp 1009-1022 (2026)
Publisher Information: Springer Nature, 2026.
Publication Year: 2026
Collection: LCC:Medicine (General); LCC:Genetics
Subject Terms: Telacebec; Oxidative Phosphorylation; Drug Combination; Antimicrobial Resistance; Terminal Oxidase; Medicine (General); R5-920; Genetics; QH426-470
Description: Abstract Pretomanid is a unique anti-tuberculosis agent that inhibits both cell-wall synthesis and bioenergetics in Mycobacterium tuberculosis. While targeting the cell wall triggers a rapid bactericidal effect on replicating mycobacteria, the release of nitric oxide is linked to bactericidal potency against antibiotic-tolerant, non-replicating subpopulations through interference with the electron transport chain. Nonetheless, the specific molecular target(s) of the drug remain unknown. Through the utilization of genetic and chemical biology approaches, we present evidence that pretomanid inhibits both the cytochrome bcc:aa 3 and bd oxidase respiratory branches. This property leads to a pronounced synergy with telacebec (Q203), a clinical-stage drug targeting the cytochrome bcc:aa 3 , while concurrently curtailing the emergence of resistance to pretomanid. Furthermore, the incorporation of the cytochrome bd oxidase inhibitor ND-011992 resulted in a triple drug combination highly bactericidal against antibiotic-tolerant, non-replicating as well as replicating M. tuberculosis. The combination of pretomanid and drugs targeting the terminal oxidases holds the potential to serve as the cornerstone for an efficacious sterilizing drug regimen against tuberculosis.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1757-4684
Relation: https://doaj.org/toc/1757-4684
DOI: 10.1038/s44321-026-00378-9
Access URL: https://doaj.org/article/61e2a2e16ba04f85bf6aaf92e4e9b2ad
Accession Number: edsdoj.61e2a2e16ba04f85bf6aaf92e4e9b2ad
Database: Directory of Open Access Journals